Roche floats record-setting $16B bond issue

For us pharma-watchers, today's news that Roche raised $16 billion from a bond sale means that it's that much closer to a takeover of Genentech. But to market-watchers, the debt sale is a sign that the corporate bond market is alive and well. And for recordbook-keepers, the Roche sale was the largest U.S. dollar-denominated corporate bond sale ever.

Fact is, Roche's decision to bypass banks in favor of the bond markets says a couple other things, too: That the Swiss pharma wasn't confident that the troubled banking system could come through to finance the $42 billion buyout--but it is confident of eventually sealing a deal with Genentech. Otherwise, why risk paying interest on billions in bonds?

It's the second big bond sale in pharma this month. You'll recall that Novartis sold $5 billion worth about a week ago, stocking the drugmaker's coffers for "financial flexibility."

- read the story in the Wall Street Journal

Suggested Articles

Imbruvica has enjoyed a nice run in previously untreated CLL over the last few years. But major competition is here in the form of AZ's Calquence.

Pennsylvania's Supreme Court revived thousands of lawsuits alleging the antipsychotic med Risperdal caused males to develop breasts.

In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.